title: Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment.
abstract: The International Working Group on the Diabetic Foot appointed an expert panel to provide evidence-based guidance on the management of osteomyelitis in the diabetic foot. Initially, the panel formulated a consensus scheme for the diagnosis of diabetic foot osteomyelitis (DFO) for research purposes, and undertook a systematic review of the evidence relating to treatment. The consensus diagnostic scheme was based on expert opinion; the systematic review was based on a search for reports of the effectiveness of treatment for DFO published prior to December 2006. The panel reached consensus on a proposed scheme that assesses the probability of DFO, based on clinical findings and the results of imaging and laboratory investigations. The literature review identified 1168 papers, 19 of which fulfilled criteria for detailed data extraction. No significant differences in outcome were associated with any particular treatment strategy. There was no evidence that surgical debridement of the infected bone is routinely necessary. Culture and sensitivity of isolates from bone biopsy may assist in selecting properly targeted antibiotic regimens, but empirical regimens should include agents active against staphylococci, administered either intravenously or orally (with a highly bioavailable agent). There are no data to support the superiority of any particular route of delivery of systemic antibiotics or to inform the optimal duration of antibiotic therapy. No available evidence supports the use of any adjunctive therapies, such as hyperbaric oxygen, granulocyte-colony stimulating factor or larvae. We have proposed a scheme for diagnosing DFO for research purposes. Data to inform treatment choices in DFO are limited, and further research is urgently needed.
authors.affiliation: Bone Infection Unit, Nuffield Orthopaedic Centre NHS Trust, Headington, Oxford, UK. tony.berendt@noc.anglox.nhs.uk
authors.forename: A R
authors.initials: AR
authors.lastname: Berendt
authors.forename: E J G
authors.initials: EJ
authors.lastname: Peters
authors.forename: K
authors.initials: K
authors.lastname: Bakker
authors.forename: J M
authors.initials: JM
authors.lastname: Embil
authors.forename: M
authors.initials: M
authors.lastname: Eneroth
authors.forename: R J
authors.initials: RJ
authors.lastname: Hinchliffe
authors.forename: W J
authors.initials: WJ
authors.lastname: Jeffcoate
authors.forename: B A
authors.initials: BA
authors.lastname: Lipsky
authors.forename: E
authors.initials: E
authors.lastname: Senneville
authors.forename: J
authors.initials: J
authors.lastname: Teh
authors.forename: G D
authors.initials: GD
authors.lastname: Valk
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017719:Diabetic Foot / Q000150:complications*; D003937:Diagnosis, Differential; D006801:Humans; D010019:Osteomyelitis / Q000175:diagnosis* / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D011379:Prognosis
chemical_list: D000900:Anti-Bacterial Agents